Session » Vasculitis – ANCA-Associated Poster II

Abstract Number: 1661

Circulating Cell Free DNA Released from Eosinophils Is a Practical Biomarker in Patients with Eosinophilic Granulomatosis with Polyangiitis

Abstract Number: 1662

Does PR3-ANCA+ Eosinophilic Granulomatosis with Polyangiitis (Churg–Strauss)Really Exist?

Abstract Number: 1663

Assessments of Quality of Life in Patients with Eosinophilic Granulomatosis with Polyangiitis

Abstract Number: 1664

Reducing the Number of Rituximab Infusions at Onset of Maintenance Therapy for ANCA-associated Vasculitides: Results of a Post Hoc Analysis from a Randomized–controlled Trial

Abstract Number: 1665

Glucocorticoids in Incident ANCA-Associated Vasculitis (AAV) Patients – A Study of Routine Clinical Practice in the EU Demonstrates Prolonged Use and Temporal Relationship to Adverse Events and Infections

Abstract Number: 1666

Maintenance Treatment in ANCA Associated Vasculitis in Real World Clinical Practice – Burden of Disease, Use of Glucocorticoids and Impact on Patient Functional Status Remain Major Problems

Abstract Number: 1667

Long Term Outcome of Hydralazine-Associated Vasculitis

Abstract Number: 1668

Granulomatosis with Polyangiitis: Data from the French Vasculitis Study Group Registry

Abstract Number: 1669

Comparison of Mizoribine with Azathioprine in Efficacy and Safety for ANCA-Associated Vasculitis

Abstract Number: 1670

Evaluation of Subclinical Coronary Atherosclerosis in ANCA-associated Small Vessel Vasculitides (AAVs) Compared to Matched Controls Through Visual Assessment of Coronary Arterial Calcium (CAC) Score Using Non-Gated Chest Computed Tomography (CT)

Abstract Number: 1671

Hospital Admissions and Mortality in Patients with ANCA-associated Vasculitis

Abstract Number: 1672

Use of Rituximab for the Treatment of ANCA-Associated Vasculitis in Canada, 2010-2018

Abstract Number: 1673

Factors Associated with Overall and First-Year Mortality in Turkish Patients with ANCA-Associated Vasculitides: Retrospective, Multicentre Trial

Abstract Number: 1674

Survival in ANCA-Associated Vasculitis in a Latin-American Center: 28 Years of Experience

Abstract Number: 1675

A Retrospective Cohort Study Using Clinical Notes and Latent Topic Modeling to Characterize the Natural History of ANCA-Associated Vasculitis

Abstract Number: 1676

Does Pneumocystis Jiroveci Pneumonia (PJP) Prophylaxis Prevent Hospitalizations for Other Infections in Vasculitis Patients?

Abstract Number: 1677

Management of Severe Renal Disease in Anti-Neutrophil-Cytoplasmic-Antibodies Associated Vasculitis: Role of Rituximab and Plasma Exchange?

Abstract Number: 1678

Interstitial Lung Disease in ANCA Associated Vasculitis: A Single Center Retrospective Analysis

Abstract Number: 1679

Adaptive Study Design of a Randomized, Multicenter, 2-Part Phase 2 Trial of Replacement of Glucocorticoids by IFX-1, a C5a Inhibitor, in Active Granulomatosis with Polyangiitis and Microscopic Polyangiitis

Abstract Number: 1680

Design of a Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of 2 Different Dose Regimens of IFX-1, a C5a Inhibitor, as an Add-On Therapy for Granulomatosis with Polyangiitis or Microscopic Polyangiitis

Abstract Number: 1681

The Association of Reduced Low-Density Lipoprotein (LDL) Cholesterol Levels with ANCA-Associated Vasculitis (AAV)

Abstract Number: 1682

Inpatient Epidemiology of Granulomatosis with Polyangiitis in the United States

Abstract Number: 1683

Cardiac Involvement of Eosinophilic Granulomatosis with Polyangiitis (Churg–Strauss): Initial Manifestations and Outcomes Based on Data from a Monocenter Patient Cohort

Abstract Number: 1684

Remission and Low Disease Activity State in Patients with Granulomatosis with Polyangiitis and Microscopic Polyangiitis: Prevalence and Impact on Damage Accrual